1016 GMT - Novartis's raised guidance reflects its solid sales performance, Intron Health analysts say in a note. Meanwhile, the Swiss drugmaker benefited from some U.S. revenue deduction adjustments, the analysts say. Its breast cancer drug Kisqali, blood-disorder treatment Fabhalta and leukemia treatment Scemblix beat consensus estimates, while eye drug Lucentis missed views. Its key growth drivers--heart drug Entresto and psoriasis treatment Cosentyx--were in line with expectations, they add. Shares are up 0.95% at 94.28 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 29, 2025 06:16 ET (10:16 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。